A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
Status:
Completed
Trial end date:
2015-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether monthly subcutaneous administration of
LBR-101 (fremanezumab) is safe and provides migraine prevention in subjects with high
frequency episodic migraine.